• Explore /
  • Poster
  • / Preclinical and early clinical activity of the oral selective inhibitor of nuclear export (SINE) exportin 1 (XPO1) antagonist KPT-330 (Selinexor) in patients (pts) with platinum-resistant/refractory ovarian cancer (OvCa).

Preclinical and early clinical activity of the oral selective inhibitor of nuclear export (SINE) exportin 1 (XPO1) antagonist KPT-330 (Selinexor) in patients (pts) with platinum-resistant/refractory ovarian cancer (OvCa).

Abstract Poster

Authors

null

John Martignetti

Mount Sinai School of Medicine, New York, NY

John Martignetti , Albiruni R.A. Razak , Ying Chen , Nashat Y. Gabrail , John F. Gerecitano , Catalina Camacho , Elena Pereira , Peter Remsen Dottino , Sharon Shacham , Dilara McCauley , Tami Rashal , Jean-Richard Saint-Martin , Eran Shacham , Darcy Vincett , Michael Kauffman , Mansoor Raza Mirza , Morten Sorensen

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2014 ASCO Annual Meeting

Session Type

Poster Highlights Session

Session Title

Gynecologic Cancer

Track

Gynecologic Cancer

Sub Track

Ovarian Cancer

Clinical Trial Registration Number

NCT01607905

Citation

J Clin Oncol 32:5s, 2014 (suppl; abstr 5522)

DOI

10.1200/jco.2014.32.15_suppl.5522

Abstract #

5522

Poster Bd #

11

Abstract Disclosures

Similar Posters

First Author: Ulrik Niels Lassen

First Author: Morten Mau-Soerensen

First Author: Mrinal M. Gounder

First Author: Karen W. L. Yee